Connect with us

Hi, what are you looking for?

Stock

Eli Lilly gets nod to launch weight-loss drug in Hong Kong – Bloomberg News

(Reuters) – Eli Lilly (NYSE:LLY) expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported on Sunday.

The company has received the Hong Kong government approval to sell its tirzepatide injections — branded as Mounjaro — in a device called Kwikpen for both long-term weight management and type 2 diabetes, Eli Lilly told Bloomberg in a statement.

This post appeared first on investing.com






    You May Also Like

    Economy

    A U.N. human rights group confirmed Hamas’ leader in Lebanon, who was recently killed by Israeli strikes, was their employee.  Fateh Sherif was killed...

    Stock

    Investing.com — Boeing (NYSE:BA) is exploring potential sales of its assets as part of a bid to shore up its finances, according to The Wall...

    Investing

    Astron (ASX:ATR) and Energy Fuels (TSX:EFR,NYSEAMERICAN:UUUU) have completed the establishment of a joint venture to advance the Australia-based Donald rare earths and mineral sands...

    Stock

    By Daniel Catchpole, Allison Lampert and Matt McKnight SEATTLE (Reuters) -Boeing factory workers are voting on Wednesday on a new contract proposal that could...

    Disclaimer: balanceandcharge.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 balanceandcharge.com